Basic Information
Odomzo
Regulatory Information
EMEA/H/C/002839
Authorised
August 14, 2015
June 25, 2015
10
April 26, 2021
Company Information
the netherlands
Polarisavenue 87 2132JH Hoofddorp
Sun Pharmaceutical Industries (Europe) B.V.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Odomzo. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Odomzo. For practical information about using Odomzo, patients should read the package leaflet or contact their doctor or pharmacist.